

Sl. No.	PARTICULARS	STANDALONE					
		For the Quarter Ended			For 6 Months Ended		For the Year Ended
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
	(1)	(2)	(3)	(4)	(5)	(6)	
1	Income						
	Revenue from operations	27,840.18	33,879.91	30,098.83	61,720.09	56,478.96	1,32,022.21
	Other Income	1,038.94	1,089.75	3,833.50	2,128.69	4,411.79	18,778.80
	Total income	28,879.12	34,969.66	33,932.33	63,848.78	60,890.75	1,50,801.01
2	Expenses						
	a) Cost of materials consumed	8,433.67	11,229.40	11,885.90	19,663.07	21,069.86	45,945.64
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	33.02	(1,564.13)	(2,628.34)	(1,531.11)	(4,137.25)	(6,035.21)
	d) Employee benefits expense	2,588.69	2,479.26	2,319.43	5,067.95	4,435.32	10,048.39
	e) R & D expense	207.46	223.23	366.94	430.69	602.18	1,035.45
	f) Finance costs	29.03	143.25	117.51	172.28	330.06	623.10
	g) Depreciation and amortisation expenses	1,075.57	1,054.78	917.70	2,130.35	1,817.03	3,909.71
	h) Manufacturing Expenses	4,449.52	4,138.69	4,373.88	8,588.21	8,258.71	17,318.86
	i) Other Expenses	1,463.55	1,899.49	1,603.51	3,363.04	2,610.98	5,710.25
	Total expenses	18,280.51	19,603.97	18,956.53	37,884.48	34,986.89	78,556.19
3	Profit before exceptional items & Tax (1-2)	10,598.61	15,365.69	14,975.80	25,964.30	25,903.86	72,244.82
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	10,598.61	15,365.69	14,975.80	25,964.30	25,903.86	72,244.82
6	Tax Expenses						
	a) Current tax	2,562.47	3,888.10	3,278.01	6,450.57	5,994.36	15,763.03
	b) Deferred tax	143.86	72.42	178.03	216.28	245.62	671.91
7	Net Profit/ (Loss) for the period/year(5-6)	7,892.28	11,405.17	11,519.76	19,297.45	19,663.88	55,809.88
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(25.49)	(25.48)	(27.98)	(50.97)	(55.94)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.42	6.41	7.05	12.83	14.08	25.66
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(19.07)	(19.07)	(20.93)	(38.14)	(41.86)	(76.29)
9	Total Comprehensive Income for the period (7+8)	7,873.21	11,386.10	11,498.83	19,259.31	19,622.02	55,733.59
10	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	1,49,523.67
12	Earning Per Share (EPS)-Face value of Rs.1/- each)						
	a) Basic	3.10	4.48	4.53	7.58	7.72	21.92
	b) Diluted	3.10	4.48	4.53	7.58	7.72	21.92
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For 6 Months Ended		For the Year Ended
		30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
	(1)	(2)	(3)	(4)	(5)	(4)	
1	Income						
	Revenue from operations	27,840.18	33,879.91	30,098.83	61,720.09	56,478.96	1,32,022.21
	Other Income	1,092.00	1,103.31	504.11	2,195.31	1,082.40	9,238.03
	Total income	28,932.18	34,983.22	30,602.94	63,915.40	57,561.36	1,41,260.24
2	Expenses						
	a) Cost of materials consumed	8,575.01	11,273.55	11,885.90	19,848.56	21,069.86	45,945.64
	b) Purchases of stock-in-trade			-			
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	21.93	(1,564.13)	(2,628.34)	(1,542.20)	(4,137.25)	(6,035.21)
	d) Employee benefits expense	2,864.78	2,658.56	2,319.43	5,523.34	4,435.32	10,048.39
	e) R & D expense	207.46	223.23	366.94	430.69	602.18	1,035.45
	f) Finance costs	29.34	145.16	117.51	174.50	330.06	623.10
	g) Depreciation and amortisation expense	1,203.05	1,150.46	917.70	2,353.51	1,817.03	3,909.71
	h) Manufacturing Expenses	4,614.82	4,230.95	4,373.88	8,845.77	8,258.71	17,318.86
	i) Other Expenses	1,568.24	1,969.53	1,603.52	3,537.77	2,611.70	5,766.55
	Total expenses	19,084.63	20,087.31	18,956.54	39,171.94	34,987.61	78,612.49
3	Profit before exceptional items, Tax & share in profit/(Loss) of Associates (1-2)	9,847.55	14,895.91	11,646.40	24,743.46	22,573.75	62,647.75
4	Add: Share of profit/(Loss) of Associates	-	-	1,746.33	-	4,111.23	4,111.23
5	Profit before exceptional items, Tax (3+4)	9,847.55	14,895.91	13,392.73	24,743.46	26,684.98	66,758.98
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	9,847.55	14,895.91	13,392.73	24,743.46	26,684.98	66,758.98
8	Tax Expenses						
	a) Current tax	2,498.06	4,069.28	3,516.22	6,567.34	6,232.57	19,040.47
	b) Deferred tax	143.86	72.42	178.03	216.28	245.62	2,338.02
9	Net Profit/ (Loss) for the period/year(7-8)	7,205.63	10,754.21	9,698.48	17,959.84	20,206.79	45,380.49
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(25.60)	(25.57)	(27.98)	(51.17)	(55.94)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.42	6.41	7.05	12.83	14.08	25.66
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(19.18)	(19.16)	(20.93)	(38.34)	(41.86)	(76.29)
11	Total Comprehensive Income for the period (9 + 10)	7,186.45	10,735.05	9,677.55	17,921.50	20,164.93	45,304.20
12	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
13	Other Equity	-	-	-	-	-	1,50,172.39
14	Earning Per Share (EPS)- (Face value of Rs.1/- each)						
	a) Basic -	2.83	4.22	3.81	7.06	7.94	17.83
	b) Diluted	2.83	4.22	3.81	7.06	7.94	17.83
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th November, 2022. The above results have been subjected to limited review by the statutory auditors of the company.
 - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA and Casper Pharma Pvt Ltd, w.e.f. from 22nd April '2022.
 - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5) The other Income (Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q2 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the dividends received and Rs.1080.41 lacs pertaining to Gain on Investments on part disinvestment of Capital from our Subsidiary, Suven Pharma, Inc. The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs) withholding tax paid on such dividend by our subsidiary.
 - 6) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec' 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar' 2022.
 - 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, (SEZ company) engaged in formulations business for USD 20.50Mn and has become a Wholly Owned Subsidiary of the Company w.e.f 22nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 each with a premium of Rs.70.00 per share for Rs.4172.92 Lacs.
 - 8) The USFDA completed pre-approval inspection at Casper Pharma formulations manufacturing facility. The inspection was conducted from 25 through 29, July 2022. The audit was part of the agency's inspection for three applications filed and slated to be manufactured at this site. The audit completed successfully with Zero observations and at the end of the inspection no form 483 was issued by USFDA and subsequently received EIR from USFDA.
 - 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

Place : Hyderabad
Date : 8th November, 2022

Venkateswarlu Jasti
Managing Director
DIN: 00278028

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30/09/2022	31/03/2022	30/09/2022	31/03/2022
	Un-Audited	Audited	Un-Audited	Audited
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	51,861.52	53,055.18	59,104.65	53,055.18
(b) Capital Work-in-Progress	8,692.37	2,999.38	8,692.37	2,999.38
(c) Other Intangible Assets	203.67	223.64	6,229.50	223.64
(d) Intangible assets under development	1.03	-	1.03	-
(e) Right of use of assets	82.65	140.56	1,686.35	140.56
(f) Financial Assets				
I. Investments	31,721.01	11,867.29	11,709.66	11,709.67
II. Loans	1.95	6.95	1.95	6.95
III. Other Financial Assets	596.99	539.21	597.00	1,269.59
(g) Deferred tax assets (net)	-	-	-	-
(h) Non-Current tax assets (net)	-	-	-	-
(i) Other non current assets	299.95	760.56	329.52	760.56
Total Non-Current assets	93,461.14	69,592.77	88,352.03	70,165.53
2 Current assets				
(a) Inventories	31,717.85	28,341.73	31,830.79	28,341.73
(b) Financial Assets				
I. Investments	29,235.01	48,122.24	32,730.17	48,122.24
II. Trade Receivables	11,115.45	23,637.23	11,115.45	23,637.23
III. Cash and Cash equivalents	4,401.70	3,021.05	6,657.01	4,456.38
IV. Bank balances otherthan (III) above	1,842.86	274.20	1,842.86	274.20
V. Loans	16.39	18.63	16.39	18.63
(c) Current Tax asset(net)	-	-	-	-
(d) Other current assets	7,463.11	7,480.94	8,056.87	7,942.79
Total Current assets	85,792.37	1,10,896.02	92,249.54	1,12,793.20
TOTAL - ASSETS	1,79,253.51	1,80,488.79	1,80,601.57	1,82,958.73
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,545.65	2,545.65	2,545.65	2,545.65
(b) Other Equity	1,48,417.79	1,49,523.67	1,47,759.91	1,50,172.39
Equity attributable to owners of the company	1,50,963.44	1,52,069.32	1,50,305.56	1,52,718.04
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	54.07	46.29	54.07	46.29
II. Borrowings	2,019.86	2,844.04	2,019.86	2,844.04
(b) Provisions	889.45	889.45	940.92	889.45
(c) Deferred tax Liabilities (net)	3,943.00	3,739.55	5,632.40	5,431.51
(d) Other non current liabilities	-	-	-	-
Total non-current liabilities	6,906.38	7,519.33	8,647.25	9,211.29
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	37.18	109.09	37.18	109.09
II. Borrowings	7,036.85	6,713.31	7,036.85	6,713.31
III. Trade payables				
a) To Micro & Small Enterprises	2,266.97	200.20	2,266.97	200.20
b) Other than Micro & Small Enterprises	6,159.92	10,389.85	6,288.62	10,389.85
IV. Other Financial Liabilities	2,027.48	2,126.01	2,167.60	2,255.27
(b) Current Tax liabilities (Net)	1,330.60	364.22	1,307.52	364.22
(c) Provision Employee benefits	757.53	407.53	759.94	407.53
(d) Other Current liabilities	1,767.16	589.93	1,784.08	589.93
	21,383.69	20,900.14	21,648.76	21,029.40
Total Liabilities	28,290.07	28,419.47	30,296.01	30,240.69
TOTAL - EQUITY AND LIABILITIES	1,79,253.51	1,80,488.79	1,80,601.57	1,82,958.73

For Seven Pharmaceuticals Ltd

 Place : Hyderabad
 Date: 8th November, 2022

 Venkateswarlu Jasti
 Managing Director
 DIN: 00278028

SUVEN PHARMACEUTICALS LIMITED			
Standalone Statement of Cash flows for the period ended 30th September, 2022			
(All amounts in Indian Rupees in Lakhs, unless otherwise stated)			
Particulars		For the period ended 30th September 2022	For the period ended 30th September 2021
A. Cash flow from operating activities			
Profit before tax		25,964.30	25,903.86
Adjustments :			
Depreciation and amortisation expense		2,085.09	1,775.48
Interest Income		(283.70)	(16.60)
Finance Cost		172.28	330.06
Gain on sale of Current Investment		(585.93)	(438.34)
Dividend received from WOS		-	(3,329.39)
Effects of foreign exchange rates (Unrealized)		46.82	(51.83)
Loss/(Profit) on disposal of Property, plant & equipment		0.65	(0.06)
Operating profit before working capital changes		27,399.51	24,173.18
Adjustments for (Increase)/decrease in operating assets			
Trade Receivables		12,474.95	(6,060.03)
Inventories		(3,376.12)	(6,354.23)
Other non current assets		57.91	(30.94)
Other current assets		17.83	(308.49)
Adjustments for Increase/(decrease) in operating liabilities			
Trade Payables		(2,163.17)	1,519.94
Short term provision		299.03	(1.75)
Other financial liabilities		(280.13)	642.47
Other current liabilities		1,177.23	462.45
Cash generated from operating activities		35,607.04	14,042.59
Income taxes paid (net of refunds)		(5,484.18)	(5,642.47)
Net Cash flows from operating activities	(A)	30,122.86	8,400.12
B. Cash flow from Investing activities			
Payments for Purchase of property, plant and equipment		(5,951.65)	(4,245.15)
Proceeds from sale of Property, plant & equipment		7.20	0.06
Changes in Investments		(19,853.72)	-
Dividend received from WOS		-	3,329.39
Fixed deposits/margin money-placed/matured		(57.79)	(18.89)
Sale/(purchase) of mutual funds		19,473.16	(2,449.37)
Bank balances not considered as cash and cash equivalents		(1,548.13)	(7.70)
Net cash flow from /(used in) investing activities	(B)	(7,930.93)	(3,391.65)
C. Cash flows from financing activities			
(Repayment)/Proceeds from long term borrowings		(824.18)	(125.91)
(Repayment)/Proceeds from short term borrowings		323.55	(1,167.91)
Other non current financial assets		5.00	-
Other current financial assets		2.25	2.30
Changes In Lease Liability		(64.13)	33.83
Finance Cost		(172.27)	(330.06)
Interest received		283.70	16.60
Dividends paid to equity holders (including dividend distribution tax)		(20,365.20)	(2,545.65)
Net cash flow from /(used In) financing activities	(C)	(20,811.28)	(4,116.80)
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	1,380.65	891.68
Cash and cash equivalents as at the beginning of the year		3,021.05	709.14
Effect of exchange differences on restatement on foreign currency cash & cash equivalents		-	(0.03)
Cash and cash equivalents at the end of the year		4,401.70	1,600.79

For Suven Pharmaceuticals Ltd

Venkateswarlu Jasti
Managing Director
DIN: 00278028

Place: Hyderabad

Date: 08th November 2022

SUVEN PHARMACEUTICALS LIMITED
Consolidated Statement of Cash flows for the period ended 30th September, 2022

(All amounts in Indian Rupees in Lakhs, unless otherwise stated)

Particulars	For the period ended 30th September 2022	For the period ended 30th September 2021
A. Cash flow from operating activities		
Profit before tax	24,743.46	26,684.97
Adjustments :		
Depreciation and amortisation expense	2,292.63	1,775.48
Interest Income	(294.40)	(16.60)
Finance Cost	174.50	330.06
Gain on sale of Current Investment	(639.54)	(438.34)
Effects of foreign exchange rates (Unrealized)	46.82	(51.83)
Loss/(Profit) on disposal of Property, plant & equipment	0.65	(0.06)
Operating profit before working capital changes	26,324.12	28,283.68
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	12,474.95	(6,060.03)
Inventories	(3,489.07)	(6,354.23)
Other non current assets	(1,545.79)	(30.94)
Other current assets	(114.07)	(308.49)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(2,034.46)	1,519.94
Long term provision	51.47	
Short term provision	301.24	(1.75)
Other financial liabilities	(340.59)	641.21
Other current liabilities	1,194.15	462.45
Cash generated from operating activities	32,821.95	18,151.84
Income taxes paid (net of refunds)	(5,682.26)	(5,880.68)
Net Cash flows from operating activities	(A) 27,139.69	12,271.16
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(19,374.76)	(4,245.15)
Proceeds from sale of Property, plant & equipment	7.20	0.06
Changes in Investments	-	(468.73)
Foreign currency translation reserve	75.23	50.99
Fixed deposits/margin money-placed/matured	672.59	(18.89)
Sale/(purchase) of mutual funds	16,031.62	(2,449.37)
Bank balances not considered as cash and cash equivalents	(1,548.13)	(7.70)
Net cash flow from /(used in) investing activities	(B) (4,136.25)	(7,138.78)
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	(824.18)	(125.91)
(Repayment)/Proceeds from short term borrowings	323.55	(1,167.91)
Other non current financial assets	5.00	-
Other current financial assets	2.25	2.30
Changes In Lease Liability	(64.13)	33.83
Finance Cost	(174.50)	(330.06)
Interest received	294.40	16.60
Dividends paid to equity holders (including dividend distribution tax)	(20,365.20)	(2,545.65)
Net cash flow from /(used In) financing activities	(C) (20,802.81)	(4,116.80)
Net increase/(decrease) in cash and cash equivalents	(A+B+C) 2,200.63	1,015.58
Cash and cash equivalents as at the beginning of the year	4,456.38	718.23
Effect of exchange differences on restatement on foreign currency cash & cash equivalents	-	(0.03)
Cash and cash equivalents at the end of the year	6,657.01	1,733.78

For Suvan Pharmaceuticals Ltd

Venkateswarlu Jasti
Managing Director
DIN: 00278028

Place: Hyderabad

Date: 08th November 2022